A Phase 1 interventional study of Lu AF28996 in Parkinson Disease, sponsored by H. Lundbeck A/S. Completed at 15 sites in 5 countries. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Parkinson Disease by H. Lundbeck A/S — 2 open to participants now, 2 under way, none of them phase 3. Parkinson Disease · H. Lundbeck A/S.
Among the 21 studies in Parkinson Disease by H. Lundbeck A/S, this one is the 13th largest by enrollment, is one of 2 that started in 2020, is one of 10 in phase 1, and was the 18th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →2 of the 21 studies in Parkinson Disease by H. Lundbeck A/S are open now, in 5 countries. Recruiting first, the newest first:
H. Lundbeck A/S · Sites in United States, Czechia, Germany and 1 more country
Ages 40–85
H. Lundbeck A/S · Sites in China
Ages 35–85
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 35 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 64 across the 21 interventional studies. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
1 of the studies in Parkinson Disease by H. Lundbeck A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07513441H. Lundbeck A/SA Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Parkinson Disease by H. Lundbeck A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
The study consists of different parts. Part A of the study will consist of once daily (OD) cohorts (OD Cohort 1 to 3), as well as twice daily (BID) cohorts (BID Cohorts A1 and A2). Part B will consist of 3 cohorts (Cohorts B1, B2, and B3) whereby participants will be administered Lu AF28996 BID.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Part A will receive ascending oral doses of Lu AF28996 OD for 14 days in all OD cohorts, followed by down-titration as per Investigator's judgement. For the BID Cohort A1, participants will receive Lu AF28996 BID for 24 days, followed by down-titration as per Investigator's judgement. For the BID Cohort A2, participants will receive Lu AF28996 BID for 39 days, followed by down-titration as per Investigator's judgement. Participants in Part B (Cohorts B1, B2, and B3) will receive Lu AF28996 BID for 41 days, followed by down-titration as per Investigator's judgement
Drug: Lu AF28996
capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
Number of Participants with Treatment-emergent Adverse Events
Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)
Time frame: From Baseline to 5.5 Months
Cmax of Lu AF28996
Maximum observed plasma concentration of Lu AF28996
Time frame: 0 (predose) to 24 hours postdose on Day 1 to Day 47
Tmax of Lu AF28996
Nominal Time Corresponding to the Occurrence of Cmax
Time frame: 0 (predose) to 24 hours postdose on Day 1 to Day 47
Ran from Feb 2020 to primary completion in Oct 2025, 67 months.
Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 67 months is above that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lu AF28996